Solasia Pharma K.K. (4597.T) JPX

Currency In JPY

Solasia Pharma K.K.

Address

Sumitomo Fudosan Shiba-Koen Tower

Tokyo, 105-0011

Japan

Phone

81 3 5843 8045

Website

https://www.solasia.co.jp

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

First IPO Date

March 27, 2017

Key Executives

Name	Title	Pay	Year Born
Yoshihiro Arai	President, Chief Executive Officer & Representative Director	0	1960
Yasumitsu Shimada	Accounting Manager	0	N/A
Yasuaki Manabe	Head of Marketing Division	0	N/A
Wataru Kobayashi	Head of Reliability Assurance Division	0	N/A
Toshio Miyashita	Chief Financial Officer, Head of Management Headquarters & Director	0	1967
Kozo Yao	Head of Business Development	0	N/A
Fumiko Nagahama	Head of Product Development Division	0	N/A
Hikaru Osawa	Head of Production Management Division	0	N/A

Description

Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil oral liquid), designed for the protection and relief of oral pain and inflammation (mucositis/stomatitis) resulting from cancer chemotherapy and radiation. Additionally, they offer SP-01 (Sancuso), a transdermal patch that delivers granisetron, an anti-emetic, into the bloodstream to manage chemotherapy-induced nausea and vomiting. Solasia Pharma's development pipeline features SP-02 (Darinaparsin), a mitochondrial-targeted agent that has successfully completed Phase III clinical trials for a range of hematologic and solid cancers. Also in Phase III clinical study is SP-05 (Arfolitixorin), which aims to bolster the anti-tumor effectiveness of fluorouracil in various cancers, including pancreatic, breast, stomach, and head and neck cancers. In its pre-clinical stage, SP-04 is being developed to address chemotherapy-induced peripheral neuropathy.